Analyst Rating: Will Pardes Biosciences Inc (PRDS) Stock Do Better Than the Market?

Monday, April 10, 2023 02:12 PM | InvestorsObserver Analysts

Mentioned in this article

Analyst Rating: Will Pardes Biosciences Inc (PRDS) Stock Do Better Than the Market?

Wall Street is positive on Pardes Biosciences Inc (PRDS). On average, analysts give PRDS a Buy rating. The average price target is $4.083, which means analysts expect the stock to add by 168.62% over the next twelve months. That average ranking earns PRDS an Analyst Rating of 26, which is better than 26% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating PRDS a Buy today. Find out what this means to you and get the rest of the rankings on PRDS!

See Full PRDS Report

Why are Analyst Ratings Important?

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve. InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

What's Happening With Pardes Biosciences Inc Stock Today?

Pardes Biosciences Inc (PRDS) stock is trading at $1.52 as of 2:11 PM on Monday, Apr 10, a drop of -$0.06, or -3.8% from the previous closing price of $1.58. The stock has traded between $1.49 and $1.65 so far today. Volume today is below average. So far 260,060 shares have traded compared to average volume of 399,855 shares. Click Here to get the full Stock Report for Pardes Biosciences Inc stock.